Amyloid PET imaging: applications beyond Alzheimer’s disease

Clinical and Translational Imaging

Volumn 3, Issue 1, 2015, Pages 39-55

  Catafau, Ana M ^a   Bullich, Santiago ^a  

^a Piramal Enterprises Limited   (India)

Author keywords

Amyloid PET; Brain trauma; Cardiac amyloidosis; Cerebral amyloid angiopathy; Down s syndrome; Multiple sclerosis

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; FLORBETABEN; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; MYELIN; PITTSBURGH COMPOUND B; PREALBUMIN; PRESENILIN 1; TAU PROTEIN;

ALZHEIMER DISEASE; BIOACCUMULATION; BRAIN HEMORRHAGE; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSE LEWY BODY DISEASE; DOWN SYNDROME; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL NEUROIMAGING; HEART AMYLOIDOSIS; HEART MUSCLE BLOOD FLOW; HUMAN; MENINGIOMA; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIPLE SCLEROSIS; NEUROANATOMICAL TRACT TRACING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; SHY DRAGER SYNDROME; TRAUMATIC BRAIN INJURY; VASCULAR AMYLOIDOSIS; WHITE MATTER LESION;

EID: 84930930149     PISSN: 22815872     EISSN: 22817565     Source Type: Journal    
DOI: 10.1007/s40336-014-0098-3     Document Type: Review

References (91)

1. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, Chan JG, Young K, Tochon-Danguy H, Masters CL, Rowe CC (2012) Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 39(6):983–989. doi:10.1007/s00259-012-2088-x
2. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, Mintun MA (2013) Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med Off Publ Soc Nucl Med 54(1):70–77. doi:10.2967/jnumed.112.109009
3. Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H (2014) [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 41(2):290–300. doi:10.1007/s00259-013-2564-y
4. Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, Cselenyi Z, Masters CL, Villemagne VL (2013) Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med Off Publ Soc Nucl Med 54(6):880–886. doi:10.2967/jnumed.112.114785
5. Vann Jones SA, O’Brien JT (2014) The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 44(4):673–683. doi:10.1017/S0033291713000494
6. Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 102(4):355–363
7. Aarsland D, Ballard CG, Halliday G (2004) Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 17(3):137–145. doi:10.1177/0891988704267470
8. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68(11):812–819. doi:10.1212/01.wnl.0000256715.13907.d3
9. Jellinger KA, Seppi K, Wenning GK (2003) Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol 106(2):188–189. doi:10.1007/s00401-003-0721-2 (author reply 190)
10. Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC (2005) Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 26(8):1183–1192. doi:10.1016/j.neurobiolaging.2004.10.006
11. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O’Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC (2011) Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med Off Publ Soc Nucl Med 52(8):1210–1217. doi:10.2967/jnumed.111.089730
12. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O’Keefe G, Nagren K, Chaudhury KR, Masters CL, Brooks DJ (2008) Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79(12):1331–1338. doi:10.1136/jnnp.2007.127878
13. Foster ER, Campbell MC, Burack MA, Hartlein J, Flores HP, Cairns NJ, Hershey T, Perlmutter JS (2010) Amyloid imaging of Lewy body-associated disorders. Mov Disord Off J Mov Disord Soc 25(15):2516–2523. doi:10.1002/mds.23393
14. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34(1):107–112. doi:10.1016/j.nbd.2008.12.008
15. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA (2008) Imaging amyloid deposition in Lewy body diseases. Neurology 71(12):903–910. doi:10.1212/01.wnl.0000326146.60732.d6
16. Claassen DO, Lowe VJ, Peller PJ, Petersen RC, Josephs KA (2011) Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. Parkinsonism Relat Disord 17(3):160–165. doi:10.1016/j.parkreldis.2010.12.006
17. Braak H, Braak E (1990) Cognitive impairment in Parkinson’s disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex. J Neural Transm Parkinson’s Dis Dement Sect 2(1):45–57
18. Ikonomovic MD, Abrahamson EE, Price JC, Hamilton RL, Mathis CA, Paljug WR, Debnath ML, Cohen AD, Mizukami K, DeKosky ST, Lopez OL, Klunk WE (2012) Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol 123(3):433–447. doi:10.1007/s00401-012-0943-2
19. Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, Johnson KA, Growdon JH (2012) Brain amyloid and cognition in Lewy body diseases. Mov Disord Off J Mov Disord Soc 27(8):965–973. doi:10.1002/mds.25048
20. Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, Walker Z, Turkheimer FE, Brooks DJ (2013) Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 38(6):938–949. doi:10.1038/npp.2012.255
21. Yong SW, Yoon JK, An YS, Lee PH (2007) A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Eur J Neurol Off J Eur Fed Neurol Soc 14(12):1357–1362. doi:10.1111/j.1468-1331.2007.01977.x
22. Jellinger KA, Attems J (2006) Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 112(3):253–260. doi:10.1007/s00401-006-0088-2
23. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci Off J Soc Neurosci 27(23):6174–6184. doi:10.1523/jneurosci.0730-07.2007
24. Kim HJ, Jeon BS, Kim YE, Kim JY, Kim YK, Sohn CH, Yun JY, Jeon S, Lee JM, Lee JY (2013) Clinical and imaging characteristics of dementia in multiple system atrophy. Parkinsonism Relat Disord 19(6):617–621. doi:10.1016/j.parkreldis.2013.02.012
25. Kitayama M, Wada-Isoe K, Irizawa Y, Nakashima K (2009) Assessment of dementia in patients with multiple system atrophy. Eur J Neurol Off J Eur Fed Neurol Soc 16(5):589–594. doi:10.1111/j.1468-1331.2009.02544.x
26. Jellinger KA (2007) More frequent Lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains. Acta Neuropathol 114(3):299–303. doi:10.1007/s00401-007-0227-4
27. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain J Neurol 132(Pt 5):1355–1365. doi:10.1093/brain/awp062
28. Charidimou A, Gang Q, Werring DJ (2012) Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 83(2):124–137. doi:10.1136/jnnp-2011-301308
29. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO (2004) Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer’s disease. Pro-CAA position statement. Neurobiol Aging 25(5):589–597. doi:10.1016/j.neurobiolaging.2004.02.003. (discussion 603–584)
30. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, van Buchem MA, Bruckmann H, Greenberg SM (2010) Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 74(17):1346–1350. doi:10.1212/WNL.0b013e3181dad605
31. Morgan D (2011) Immunotherapy for Alzheimer’s disease. J Intern Med 269(1):54–63. doi:10.1111/j.1365-2796.2010.02315.x
32. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG (2007) PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain J Neurol 130(Pt 10):2607–2615. doi:10.1093/brain/awm191
33. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain J Neurol 131(Pt 6):1630–1645. doi:10.1093/brain/awn016
34. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM (2007) Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 62(3):229–234. doi:10.1002/ana.21164
35. Dugger BN, Clark CM, Serrano G, Mariner M, Bedell BJ, Coleman RE, Doraiswamy PM, Lu M, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Zehntner SP, Carpenter AP, Joshi AD, Mintun MA, Pontecorvo MJ, Skovronsky DM, Sue LI, Beach TG (2014) Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol 73(1):72–80. doi:10.1097/nen.0000000000000028
36. Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam RN, Becker JA, Kumar A, Neal KL, Betensky RA, Frosch MP, Rosand J, Johnson KA, Viswanathan A, Salat DH, Greenberg SM (2010) Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol 68(4):545–548. doi:10.1002/ana.22099
37. Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O’Keefe G, Gong SJ, Gunawan RM, Saunder T, Ackerman U, Tochon-Danguy H, Churilov L, Phan TG, Rowe CC (2010) 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 74(6):487–493. doi:10.1212/WNL.0b013e3181cef7e3
38. Baron JC, Farid K, Dolan E, Turc G, Marrapu ST, O’Brien E, Aigbirhio FI, Fryer TD, Menon DK, Warburton EA, Hong YT (2014) Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 34(5):753–758. doi:10.1038/jcbfm.2014.43
39. Gurol ME, Dierksen G, Betensky R, Gidicsin C, Halpin A, Becker A, Carmasin J, Ayres A, Schwab K, Viswanathan A, Salat D, Rosand J, Johnson KA, Greenberg SM (2012) Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology 79(4):320–326. doi:10.1212/WNL.0b013e31826043a9
40. Gurol ME, Viswanathan A, Gidicsin C, Hedden T, Martinez-Ramirez S, Dumas A, Vashkevich A, Ayres AM, Auriel E, van Etten E, Becker A, Carmasin J, Schwab K, Rosand J, Johnson KA, Greenberg SM (2013) Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol 73(4):529–536. doi:10.1002/ana.23830
41. Yates PA, Sirisriro R, Villemagne VL, Farquharson S, Masters CL, Rowe CC (2011) Cerebral microhemorrhage and brain beta-amyloid in aging and Alzheimer disease. Neurology 77(1):48–54. doi:10.1212/WNL.0b013e318221ad36
42. Sengoku R, Matsushima S, Murakami Y, Fukuda T, Tokumaru AM, Hashimoto M, Suzuki M, Ishiwata K, Ishii K, Mochio S (2014) (11)C-PiB PET imaging of encephalopathy associated with cerebral amyloid angiopathy. Intern Med (Tokyo, Jpn) 53(17):1997–2000
43. Chetelat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F, Vandenberghe R (2013) Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. NeuroImage Clin 2:356–365. doi:10.1016/j.nicl.2013.02.006
44. Mathis CA, Kuller LH, Klunk WE, Snitz BE, Price JC, Weissfeld LA, Rosario BL, Lopresti BJ, Saxton JA, Aizenstein HJ, McDade EM, Kamboh MI, DeKosky ST, Lopez OL (2013) In vivo assessment of amyloid-beta deposition in nondemented very elderly subjects. Ann Neurol 73(6):751–761. doi:10.1002/ana.23797
45. Han BH, Zhou ML, Vellimana AK, Milner E, Kim DH, Greenberg JK, Chu W, Mach RH, Zipfel GJ (2011) Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. Mol Neurodegener 6:86. doi:10.1186/1750-1326-6-86
46. Zha Z, Choi SR, Ploessl K, Lieberman BP, Qu W, Hefti F, Mintun M, Skovronsky D, Kung HF (2011) Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Abeta plaques in cerebral amyloid angiopathy (CAA). J Med Chem 54(23):8085–8098. doi:10.1021/jm2009106
47. Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI (1994) Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 57(4):419–425
48. Goodwin L (2006) Dementia pugilistica. J Insur Med (N Y, NY) 38(4):300–302
49. McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, Riley DO, Kubilus CA, Cormier KA, Jacobs MA, Martin BR, Abraham CR, Ikezu T, Reichard RR, Wolozin BL, Budson AE, Goldstein LE, Kowall NW, Cantu RC (2013) The spectrum of disease in chronic traumatic encephalopathy. Brain J Neurol 136(Pt 1):43–64. doi:10.1093/brain/aws307
50. Kawai N, Kawanishi M, Kudomi N, Maeda Y, Yamamoto Y, Nishiyama Y, Tamiya T (2013) Detection of brain amyloid beta deposition in patients with neuropsychological impairment after traumatic brain injury: PET evaluation using Pittsburgh compound-B. Brain Inj [BI] 27(9):1026–1031. doi:10.3109/02699052.2013.794963
51. Hong YT, Veenith T, Dewar D, Outtrim JG, Mani V, Williams C, Pimlott S, Hutchinson PJ, Tavares A, Canales R, Mathis CA, Klunk WE, Aigbirhio FI, Coles JP, Baron JC, Pickard JD, Fryer TD, Stewart W, Menon DK (2014) Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol 71(1):23–31. doi:10.1001/jamaneurol.2013.4847
52. Ikonomovic MD, Uryu K, Abrahamson EE, Ciallella JR, Trojanowski JQ, Lee VM, Clark RS, Marion DW, Wisniewski SR, DeKosky ST (2004) Alzheimer’s pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol 190(1):192–203. doi:10.1016/j.expneurol.2004.06.011
53. Chen XH, Johnson VE, Uryu K, Trojanowski JQ, Smith DH (2009) A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol 19(2):214–223. doi:10.1111/j.1750-3639.2008.00176.x
54. Mitsis EM, Riggio S, Kostakoglu L, Dickstein DL, Machac J, Delman B, Goldstein M, Jennings D, D’Antonio E, Martin J, Naidich TP, Aloysi A, Fernandez C, Seibyl J, DeKosky ST, Elder GA, Marek K, Gordon W, Hof PR, Sano M, Gandy S (2014) Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury. Transl Psychiatry 4:e441. doi:10.1038/tp.2014.91
55. Mitsis EM, Bender HA, Kostakoglu L, Machac J, Martin J, Woehr JL, Sewell MC, Aloysi A, Goldstein MA, Li C, Sano M, Gandy S (2014) A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener 9:10. doi:10.1186/1750-1326-9-10
56. Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C (2006) APP duplication is sufficient to cause early onset Alzheimer’s dementia with cerebral amyloid angiopathy. Brain J Neurol 129(Pt 11):2977–2983. doi:10.1093/brain/awl203
57. Zhou ZD, Chan CH, Ma QH, Xu XH, Xiao ZC, Tan EK (2011) The roles of amyloid precursor protein (APP) in neurogenesis: implications to pathogenesis and therapy of Alzheimer disease. Cell Adhes Migr 5(4):280–292
58. Mann DM, Esiri MM (1989) The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down’s syndrome. J Neurol Sci 89(2–3):169–179
59. Mann DM (1988) Alzheimer’s disease and Down’s syndrome. Histopathology 13(2):125–137
60. Visser FE, Aldenkamp AP, van Huffelen AC, Kuilman M, Overweg J, van Wijk J (1997) Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am J Ment retard AJMR 101(4):400–412
61. Malone Q (1988) Mortality and survival of the Down’s syndrome population in Western Australia. J Ment Defic Res 32(Pt 1):59–65
62. Strauss D, Eyman RK (1996) Mortality of people with mental retardation in California with and without Down syndrome, 1986–1991. Am J Ment Retard AJMR 100(6):643–653
63. Cutler NR, Sramek JJ (2001) Review of the next generation of Alzheimer’s disease therapeutics: challenges for drug development. Prog Neuropsychopharmacol Biol Psychiatry 25(1):27–57
64. Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, Fratiglioni L, Hooshmand B, Khachaturian AS, Schneider LS, Skoog I, Kivipelto M (2014) Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med 275(3):229–250. doi:10.1111/joim.12178
65. Lannfelt L, Relkin NR, Siemers ER (2014) Amyloid-ss-directed immunotherapy for Alzheimer’s disease. J Intern Med 275(3):284–295. doi:10.1111/joim.12168
66. Landt J, D’Abrera JC, Holland AJ, Aigbirhio FI, Fryer TD, Canales R, Hong YT, Menon DK, Baron JC, Zaman SH (2011) Using positron emission tomography and carbon 11-labeled Pittsburgh compound B to image brain fibrillar beta-amyloid in adults with down syndrome: safety, acceptability, and feasibility. Arch Neurol 68(7):890–896. doi:10.1001/archneurol.2011.36
67. Handen BL, Cohen AD, Channamalappa U, Bulova P, Cannon SA, Cohen WI, Mathis CA, Price JC, Klunk WE (2012) Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimer’s Dement J Alzheimer’s Assoc 8(6):496–501. doi:10.1016/j.jalz.2011.09.229
68. Jennings D, Seibyl J, Sabbagh M, Lai F, Hopkins W, Bullich S, Gimenez M, Reininger C, Putz B, Stephens A, Catafau AM, Marek K (2015) Age dependence of brain β-amyloid deposition in Down syndrome: an [18F]florbetaben PET study. Neurology [Epub ahead of print]
69. Sabbagh MN, Fleisher A, Chen K, Rogers J, Berk C, Reiman E, Pontecorvo M, Mintun M, Skovronsky D, Jacobson SA, Sue LI, Liebsack C, Charney AS, Cole L, Belden C, Beach TG (2011) Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease. Arch Neurol 68(11):1461–1466. doi:10.1001/archneurol.2011.535
70. Hardy J (2009) The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem 110(4):1129–1134. doi:10.1111/j.1471-4159.2009.06181.x
71. Kim HY, Kim J, Lee JH (2012) Incidental finding of meningioma on C11-PIB PET. Clin Nucl Med 37(2):e36–e37. doi:10.1097/RLU.0b013e318238f25a
72. Yamamoto Y, Maeda Y, Kawai N, Kudomi N, Nishiyama Y (2013) Unexpected finding of cerebral meningioma on (11)C-PiB PET. Clin Nucl Med 38(4):292–293. doi:10.1097/RLU.0b013e3182817c8f
73. Foschini MP, D’Adda T, Bordi C, Eusebi V (1993) Amyloid stroma in meningiomas. Virchows Archiv A Pathol Anat Histopathol 422(1):53–59
74. Sachchithanantham S, Wechalekar AD (2013) Imaging in systemic amyloidosis. Br Med Bull 107:41–56. doi:10.1093/bmb/ldt021
75. Ruberg FL, Berk JL (2012) Transthyretin (TTR) cardiac amyloidosis. Circulation 126(10):1286–1300. doi:10.1161/CIRCULATIONAHA.111.078915
76. Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, Moore SC, Falk RH (2014) Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 41(9):1652–1662. doi:10.1007/s00259-014-2787-6
77. Chen W, Dilsizian V (2012) Molecular imaging of amyloidosis: will the heart be the next target after the brain? Curr Cardiol Rep 14(2):226–233. doi:10.1007/s11886-011-0239-5
78. Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, Kero T, Langstrom B, Granstam SO, Rosengren S, Vedin O, Wassberg C, Wikstrom G, Westermark P, Sorensen J (2013) In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med Off Publ Soc Nucl Med 54(2):213–220. doi:10.2967/jnumed.111.102053
79. Lhommel R, Sempoux C, Ivanoiu A, Michaux L, Gerber B (2014) Is 18F-flutemetamol PET/CT able to reveal cardiac amyloidosis? Clin Nucl Med 39(8):747–749. doi:10.1097/rlu.0000000000000492
80. Minamimoto R, Ishii K, Kubota K, Morooka M, Okasaki M, Ito K, Mitsumoto T, Nakajima K, Sato T, Mochizuki M, Okazaki O (2012) Amyloid imaging mismatch. Clin Nucl Med 37(8):807–809. doi:10.1097/RLU.0b013e318251e1d3
81. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol 55(3):306–319. doi:10.1002/ana.20009
82. Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, Cappai R, Villemagne VL (2009) Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med Off Publ Soc Nucl Med 50(2):198–204. doi:10.2967/jnumed.108.057984
83. Stankoff B, Freeman L, Aigrot MS, Chardain A, Dolle F, Williams A, Galanaud D, Armand L, Lehericy S, Lubetzki C, Zalc B, Bottlaender M (2011) Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-(1)(1)C]-2-(4′-methylaminophenyl)-6-hydroxybenzothiazole. Ann Neurol 69(4):673–680. doi:10.1002/ana.22320
84. Ito H, Shimada H, Shinotoh H, Takano H, Sasaki T, Nogami T, Suzuki M, Nagashima T, Takahata K, Seki C, Kodaka F, Eguchi Y, Fujiwara H, Kimura Y, Hirano S, Ikoma Y, Higuchi M, Kawamura K, Fukumura T, Boo EL, Farde L, Suhara T (2014) Quantitative analysis of amyloid deposition in Alzheimer Disease using PET and the radiotracer 11C-AZD2184. J Nucl Med Off Publ Soc Nucl Med 55(6):932–938. doi:10.2967/jnumed.113.133793
85. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, Hamilton RL, Ikonomovic MD, DeKosky ST, Mathis CA (2003) The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci Off J Soc Neurosci 23(6):2086–2092
86. Moll NM, Cossoy MB, Fisher E, Staugaitis SM, Tucky BH, Rietsch AM, Chang A, Fox RJ, Trapp BD, Ransohoff RM (2009) Imaging correlates of leukocyte accumulation and CXCR4/CXCL12 in multiple sclerosis. Arch Neurol 66(1):44–53. doi:10.1001/archneurol.2008.512
87. Glodzik L, Kuceyeski A, Rusinek H, Tsui W, Mosconi L, Li Y, Osorio RS, Williams S, Randall C, Spector N, McHugh P, Murray J, Pirraglia E, Vallabhajosula S, Raj A, de Leon MJ (2014) Reduced glucose uptake and Abeta in brain regions with hyperintensities in connected white matter. NeuroImage 100:684–691. doi:10.1016/j.neuroimage.2014.06.060
88. Murray ME, Vemuri P, Preboske GM, Murphy MC, Schweitzer KJ, Parisi JE, Jack CR Jr, Dickson DW (2012) A quantitative postmortem MRI design sensitive to white matter hyperintensity differences and their relationship with underlying pathology. J Neuropathol Exp Neurol 71(12):1113–1122. doi:10.1097/NEN.0b013e318277387e
89. Shimada H, Shinotoh H, Hirano S, Miyoshi M, Sato K, Tanaka N, Ota T, Fukushi K, Irie T, Ito H, Higuchi M, Kuwabara S, Suhara T (2013) β-Amyloid in Lewy body disease is related to Alzheimer’s disease-like atrophy. Mov Disord 28(2):169–175. doi:10.1002/mds.25286
90. Johnson KA, Fox NC, Sperling RA, Klunk WE (2012) Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2(4):a006213. doi:10.1101/cshperspect.a006213
91. Chao LL, Decarli C, Kriger S, Truran D, Zhang Y, Laxamana J, Villeneuve S, Jagust WJ, Sanossian N, Mack WJ, Chui HC, Weiner MW (2013) Associations between white matter hyperintensities and beta amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI. PLoS One 8(6):e65175. doi:10.1371/journal.pone.0065175